This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex: More Evidence Cystic Fibrosis Combo Therapy Improves Lung Function

CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals' (VRTX - Get Report) two-drug therapy significantly improved lung function in patients with the most common genetic mutation causing cystic fibrosis, according to final results from a mid-stage study announced Thursday.

The new data on the combination of Vertex's experimental VX-809 and currently marketed Kalydeco are culled from all 109 cystic fibrosis patients in the phase II study and build upon interim results from about half the study's patients released in May.

Based on these results, a pivotal phase III study utilizing the highest, 600 mg dose of VX-809 and Kalydeco in cystic fibrosis patients with two copies (homozygous) of the F508del gene will begin in early 2013, Vertex said.

Vertex also said it would conduct "additional studies" of the VX-809-Kalydeco combination therapy in cystic fibrosis patients with a single copy (heterozygous) of the F508del gene based on improvements in lung function seen in the phase II study.

Vertex shares are up 65% since the interim results from the VX-809-Kalydeco study were announced, in large part because projected peak sales from the company's cystic fibrosis drug business could reach $4-6 billion. Vertex closed Wednesday at $61.11.

From the start of the study through day 56, patients treated with high dose (600 mg) of VX-809 and Kalydeco experienced a 6.7% improvement in lung function compared to placebo and a 3.4% improvement within the drug treatment group. Both results were statistically significant.

Over the same time period, placebo-treated patients saw their lung function fall by 3.3%.

At the interim analysis announced in May, which encompassed half the patients in the VX-809-Kalydeco study, the placebo-adjusted and within-group improvements in lung function were 8.6% and 4%, respectively. These interim results combined patients treated with three different doses of VX-809.

Vertex did not disclose final lung function results from the phase II study Thursday for all patients across the three different doses of VX-809. The company did say that patients treated with the low- and mid-doses of VX-809 plus Kalydeco also experienced statistically significant improvements in lung function compared to placebo although the improvements were lower than what was seen with the highest dose of VX-809.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
VRTX $127.80 0.00%
AAPL $132.04 0.00%
FB $80.55 0.00%
GOOG $539.79 0.00%
TSLA $247.43 0.00%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs